2. Academic Validation
  3. Immunomodulatory properties of CD38 antibodies and their effect on anticancer efficacy in multiple myeloma

Immunomodulatory properties of CD38 antibodies and their effect on anticancer efficacy in multiple myeloma

  • Cancer Med. 2023 Oct;12(20):20332-20352. doi: 10.1002/cam4.6619.
Kamlesh Bisht 1,  Taro Fukao 1,  Marielle Chiron 2,  Paul Richardson 3,  Djordje Atanackovic 4 5,  Eduardo Chini 6,  Wee Joo Chng 7,  Helgi Van De Velde 1,  Fabio Malavasi 8 9
Affiliations

Affiliations

  • 1 Sanofi Oncology, Cambridge, Massachusetts, USA.
  • 2 Sanofi Research & Development, Vitry-sur-Seine, France.
  • 3 Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA.
  • 4 University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, Baltimore, Maryland, USA.
  • 5 Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland, USA.
  • 6 Department of Anesthesiology and Perioperative Medicine, Mayo Clinic, Jacksonville, Florida, USA.
  • 7 Cancer Science Institute of Singapore, National University of Singapore, Singapore, Singapore.
  • 8 Department of Medical Sciences, University of Turin, Torino, Italy.
  • 9 Fondazione Ricerca Molinette, Torino, Italy.
PMID: 37840445 DOI: 10.1002/cam4.6619
Abstract

Background: CD38 has been established as an important therapeutic target for multiple myeloma (MM), for which two CD38 antibodies are currently approved-daratumumab and isatuximab. CD38 is an ectoenzyme that degrades NAD and its precursors and is involved in the production of adenosine and Other metabolites.

Aim: Among the various mechanisms by which CD38 antibodies can induce MM cell death is immunomodulation, including multiple pathways for CD38-mediated T-cell activation. Patients who respond to anti-CD38 targeting treatment experience more marked changes in T-cell expansion, activity, and clonality than nonresponders.

Implications: Resistance mechanisms that undermine the immunomodulatory effects of CD38-targeting therapies can be tumor intrinsic, such as the downregulation of CD38 surface expression and expression of complement inhibitor proteins, and immune microenvironment-related, such as changes to the natural killer (NK) cell numbers and function in the bone marrow niche. There are numerous strategies to overcome this resistance, which include identifying and targeting Other therapeutic targets involved in, for example, adenosine production, the activation of NK cells or monocytes through immunomodulatory drugs and their combination with elotuzumab, or with bispecific T-cell engagers.

Keywords

CD38 antibodies; adenosine; bone marrow niche; daratumumab; immunomodulation; isatuximab; multiple myeloma.

Figures
Products
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z